Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes
Share:
(Reuters) - Reckitt Benckiser has agreed to pay up to $1.4 billion (£1.1 billion) to resolve U.S. claims that its former pharmaceuticals business Indivior before it was spun out of the company carried out an illegal scheme to boost sales of an opioid addiction treatment. The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone..